Latest research on anti-RSV

Humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). Synagis is a composite of human (95%) and murine (5%) antibody sequences. The human heavy chain sequence was derived from the constant domains of human IgG1 and the variable framework regions of the VH genes Cor (1) and Cess (2). The human lightchain sequence was derived from the constant domain of Ck and the variable framework regions of the VL gene K104 withJk-4. Palivizumab is expressed from a stable murine (mouse) myeloma cell line (NS0). Palivizumab is composed of to heavy chains (50.6 kDa each) and two light chains (27.6 kDa each), contains 1-2% carbohydrate by weight and has a molecular weight of 147.7 kDa +/- 1 kDa (MALDI-TOF)

anti-RSV interactions

Possible reasons for the difference between the Turkish (15) and other studies (5, 16, 17) include: using CLARITHROMYCIN with its greater lung penetration and potential anti-RSV activity (11), differences in sample size, attrition population characteristics, the role of chance, and increased risk of bias associated with small studies. [source, 2015]
There are only limited therapeutic agents such as palivizumab and Ribavirin that are reported against RSV, and this fact illustrates the urgent need for the development of new anti-RSV drugs [74]. [source, 2015]
Compound 22-O-(N-Me-l-valyl)-21-epi-aflaquinolone B (44) exhibited exceptional anti-RSV activity with an IC50 value of 42 nM, roughly 500 times more potent than Ribavirin, the positive control used in this study, with IC50 = 20 μM [54]. [source, 2015]
Co-cultures were then fixed with 4% Paraformaldehyde, stained with Alexa Fluor 488-conjugated test Mab (2G12, A32, 17b or Synagis), and mounted in imaging buffer for examination using the Nikon N-STORM superresolution microscope (see Methods). [source, 2015]
Moreover, Ribavirin has low anti-RSV activity (EC50 on Hep2 cells, for RSV-A virus: 30 μM) and reduced selectivity index [7], which could explain the controversial effectiveness observed in clinical settings with this drug. [source, 2015]
However, Ribavirin efficacy against RSV is limited and severe adverse effects, in particular an increased risk of anemia and mitochondrial toxicity (Canonico, 1985; Gilbert and Knight, 1986; Huggins et al., 1991), undermine its clinical use for anti-RSV therapy. [source, 2015]
Its efficacy in an in vivo mouse model equals that of Ribavirin, the only approved anti-RSV small molecule drug, but it is better tolerated and can be orally administered. [source, 2015]
Comparing with the anti-RSV activity of Ribavirin, there were significant differences in the prophylactic and virucidal effects of MBS extract and Ribavirin (P < 0.05) at the same time of incubation. [source, 2015]
Human IgG1 mAbs, Avastin (anti-VEGF [31]) and Synagis (anti-human respiratory syncytial virus [32]), were from Genentech, Inc. (San Francisco, CA) and MedImmune LLC (Gaithersburg, MD), respectively. [source, 2015]
Two humanized murine IgG1 mAbs generated against non-amyloid targets, Avastin (anti-VEGF, Genentech, Inc.) and Synagis (anti-RSV, MedImmune LLC), recognized Aβ aggregates (Fig 7A, Table 1). [source, 2015]